SUNNYVALE, Calif., May 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that clinical studies continue to validate the versatility of the company's CyberKnife® and TomoTherapy® platforms, including the next-generation Radixact® System, to accurately and efficiently treat a wide variety of indications of all complexities. The data presented at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress held in Copenhagen, Denmark demonstrate how the advanced radiotherapy delivery platforms enable medical care teams to deliver truly personalized care aligned to the needs of each patient.

"Accuray was founded with the goal of providing clinicians with technology that delivers ultra-precise radiation therapy treatments and advances the care of patients diagnosed with cancer or neurologic disorders. The data shared at ESTRO show our customers are making this aspiration a reality and reinforces the impact they are making using our cutting-edge technologies," said Suzanne Winter, president of Accuray.

Ms. Winter added, "We are committed to being the recognized innovation leader in radiation therapy by continuing to invest in technologies that provide new, effective ways to treat medical conditions that may benefit from this type of treatment and expand the available options for care. At this year's ESTRO, we are proud to highlight the advances from our partnership with C-RAD, for example, that are designed to provide customers with a solution for the Radixact System that will position it as the ideal, workhorse system for the full range of breast cancer indications, which represent up to 25% of radiation therapy patient cases."
New Data Presented at ESTRO
The CyberKnife platform's unique robotic technology, non-coplanar beam delivery and Synchrony® technology enable the treatment of more anatomical sites with ultra-hypofractionated radiotherapy, helping to make a clinical difference for patients every day.

Neurologic Disorders: sub-millimeter accuracy enables delivery of stereotactic radiosurgery (SRS) to a diverse patient population. Studies indicate CyberKnife SRS can:
Increase survival for patients with recurrent high-grade gliomas.
Offer patients with acoustic neuromas a well-tolerated, effective regimen with excellent tumor control and acceptable hearing preservation.
Provide good local control with low toxicity when treating HER2-breast cancer brain metastasis.

Rad Oncology Homepage